Overall, the pooled HR for the 11 eligible studies evaluating SF3B1 mutation on OS was 2.57(95%CI 1.68-3.94, P<0.001), which suggested that SF3B1 mutation was significantly associated with worse prognosis for CLL in OS (Figure 2B). This evidence concerns the gene SF3B1 and B-cell chronic lymphocytic leukemia.